Abstract Vosoritide is the first precision medical therapy approved to increase growth velocity in children with achondroplasia. Sharing early prescribing experiences across different regions could provide a framework for developing practical guidance for the real-world use of vosoritide. Two meetings were held to gather insight and early experience from experts in Europe, the Middle East, and the USA.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Vienna
Contact Vienna, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack